Late Breaker Abstracts: COVID-19 Vaccines, Epidemiology, and Clinical

Moderator(s)

• 

  Andrew Pavia, MD

  George and Esther Gross Presidential Professor Chief, Division of Pediatric Infectious Diseases
  University of Utah
  Salt Lake City, UT, United States

  Antimicrobial Therapy Inc (Individual(s) Involved: Self): Associate Editor; Merck, Sharpe, and Dohme (Individual(s) Involved: Self): Consultant; WebMD (Individual(s) Involved: Self): Consultant

Presentations:

• Asymptomatic Infection and Duration of Viral Shedding in Symptomatic Breakthrough Infections in a Phase 3 Study of AZD1222 (ChAdOx1 nCoV-19)
  

  Presenting Author: Magdalena Sobieszczyk, MD, MPH – Columbia University Irving Medical Center

  Co-Author: Ann R. Falsey, MD – University of Rochester

  Co-Author: Merlin L. Robb, M.D. – Walter Reed Army Institute of Research, Silver Spring, MD

  Co-Author: Hong-Van Tieu, M.D, M.S. – Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY and Laboratory of Infectious Disease Prevention, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY

  Co-Author: Julie McElrath, MD, PhD – Fred Hutchinson Cancer Research Center

  Co-Author: Lawrence Corey, MD – Fred Hutchinson Cancer Research Center

  Co-Author: Kathleen Neuzil, MD, MPH – University of Maryland School of Medicine

  Co-Author: Tina Tong, M.S. – National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

  Co-Author: Margaret Brewinski Isaacs, M.D, M.P.H – National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

  Co-Author: Jill Maaske, M.D. – AstraZeneca Pharmaceuticals LP, Gaithersburg, MD

  Co-Author: Brett Jepson, n/a – AstraZeneca Pharmaceuticals LP, Gaithersburg, MD and Cytel, Inc., Cambridge, MA

  Co-Author: Stephanie Sproule, n/a – AstraZeneca Pharmaceuticals LP, Gaithersburg, MD

  Co-Author: Elizabeth Kelly, n/a – AstraZeneca Pharmaceuticals LP, Gaithersburg, MD
• Ad26.COV2.S-Elicited Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials
  

  Co-Author: Mathieu Le Gars, n/a – Janssen Vaccines and Prevention, Leiden, The Netherlands

  Co-Author: Jerald Sadoff, MD – Janssen Infectious Diseases and Vaccines, Leiden, Zuid-Holland, The Netherlands, 2333

  Co-Author: Mandy Jongeneelen, n/a – Janssen Vaccines and Prevention, Leiden, The Netherlands

  Co-Author: Dirk Heerwegh, n/a – Janssen Research and Development, Beerse, Belgium

  Co-Author: Georgi Shukarev, MD – Janssen Vaccines and Prevention, Leiden, Netherlands

  Co-Author: Carla Truyers, n/a – Janssen Research and Development, Beerse, Belgium

  Co-Author: Anne Marit de Groot, n/a – Janssen Vaccines and Prevention, Leiden, The Netherlands

  Co-Author: Gert Scheper, n/a – Janssen Vaccines and Prevention, Leiden, The Netherlands

  Co-Author: Jenny Hendriks, n/a – Janssen Vaccines and Prevention, Leiden, The Netherlands

  Co-Author: Boerries Brandenburg, n/a – Janssen Vaccines and Prevention, Leiden, The Netherlands

  Co-Author: Frank Struyf, n/a – Janssen Research and Development, Beerse, Belgium

  Co-Author: Johan Van Hoof, n/a – Janssen Vaccines and Prevention, Leiden, The Netherlands

  Co-Author: Macaya Douoguih, MD, MPH – Janssen Vaccines and Prevention, Leiden, Netherlands

  Presenting Author: Hanneke Schuitemaker, PhD – Janssen Infectious Diseases and Vaccines, Leiden, Zuid-Holland, The Netherlands, 2333
• Lower SARS-CoV-2 IgG and Pseudovirus Neutralization Titers Post-mRNA Vaccination among People Living with HIV
  

  Presenting Author: Matthew A. Spinelli, MD, MAS – University of California, San Francisco

  Co-Author: Michael J. Peluso, MD – University of California, San Francisco

  Co-Author: Kara Lynch, PhD – University of California San Francisco

  Co-Author: Cassandra Yun, BA – UCSF

  Co-Author: David V. Glidden, PhD – University of California, San Francisco

  Co-Author: Timothy J. Henrich, MD – University of California, San Francisco

  Co-Author: Steve Deeks, MD – UCSF

  Co-Author: Monica Gandhi, MD, MPH – University of California, San Francisco
• Longitudinal antibody dynamics in children infected with SARS-CoV-2 through 6 months post-infection
  

  Presenting Author: Lauren E. Gentles – Fred Hutchinson Cancer Research Center

  Co-Author: Leanne P. Kehoe, BA – Seattle Children's Hospital

  Co-Author: Katharine D. Crawford, PhD – University of Washington

  Co-Author: Kirsten Lacombe, RN, MSN – Seattle Children's Hospital

  Co-Author: Jane Dickerson, PhD – Seattle Children’s Hospital

  Co-Author: Joanna H. Yuan, B.A. – Seattle Children's Hospital

  Co-Author: Susanna L. Schuler, BA – Seattle Children's Hospital

  Co-Author: Sankan Nyanseor, MPH – U.S. Centers for Disease Control and Prevention

  Co-Author: Sharon Saydah, PhD – Centers for Disease Control and Prevention

  Co-Author: Claire Midgley, PHD – CDC

  Co-Author: Kimberly Pringle, MD – Centers for Disease Control and Prevention

  Co-Author: Jesse Bloom, PhD – Fred Hutchinson Cancer Research Center

  Co-Author: Janet A. Englund, MD – Seattle Children's Hospital/Univ. of Washington
• Impact of SARS-CoV-2 Delta Variant on the Spectrum of Pediatric COVID-19 Disease in Arkansas
  

  Co-Author: Jose R. Romero, MD – University of Arkansas for Medical Sciences

  Co-Author: Donald E. Warden, MPH – Arkansas Department of Health

  Presenting Author: Michael Cima, PhD, MPH – Arkansas Department of Health